Keyphrases
Randomized Trial
100%
Early Breast Cancer
100%
Bisphosphonates
100%
Individual Patient Data Meta-analysis
100%
Bisphosphonate Treatment
100%
Adjuvant Bisphosphonates
100%
Distant Recurrence
66%
Rate Ratio
66%
Breast Cancer Mortality
66%
Menopausal Status
50%
Bone Recurrence
50%
Postmenopausal Women
33%
Recurrence Rate
33%
Metastasis
16%
Breast Cancer
16%
Meta-analysis
16%
Tumor Grade
16%
Estrogen Receptor Status
16%
Zoledronic Acid
16%
Concomitant Chemotherapy
16%
Ranking Method
16%
Event Rate
16%
First Recurrence
16%
Bone Fracture
16%
Intention-to-treat
16%
Breast Cancer Survival
16%
Clodronate
16%
Breast Cancer Recurrence
16%
Individual Patient Data
16%
Reduced Rate
16%
Treatment Schedule
16%
Bone Physiology
16%
Menopausal Age
16%
Aminobisphosphonates
16%
Ibandronate
16%
Primary Subgroup
16%
Medicine and Dentistry
Patient-Data
100%
Breast Cancer
100%
Meta-Analysis
100%
Recurrent Disease
100%
Bisphosphonate
100%
Cancer Mortality
44%
Recurrence Risk
22%
Neoplasm
11%
Metastatic Carcinoma
11%
Estrogen Receptor
11%
Postmenopause
11%
Intention-to-Treat Analysis
11%
Premenopause
11%
Fracture
11%
Zoledronic Acid
11%
Breast Cancer Survival
11%
Clodronic Acid
11%
Pamidronic Acid
11%
Ibandronic Acid
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Recurrent Disease
100%
Bisphosphonic Acid Derivative
100%
Cancer Mortality
44%
Recurrence Risk
22%
Neoplasm
11%
Cancer Survival
11%
Chemotherapy
11%
Estrogen Receptor
11%
Zoledronic Acid
11%
Fracture
11%
Clodronic Acid
11%
Pamidronic Acid
11%
Ibandronic Acid
11%